Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Blood Test Can Predict Severity of COVID-19

By LabMedica International staff writers
Posted on 30 Jun 2020
Doctors can now identify COVID-19 patients having the highest risk of severe illness and pinpoint those most likely to need a ventilator by simply examining their blood.

This discovery by researchers from the University of Virginia (UVA) School of Medicine (Charlottesville, VA, USA) could lead to new treatments for the prevention of deadly “cytokine storms” seen in severe cases of COVID-19. More...
It also may help explain why diabetes contributes to worse outcomes in patients with the coronavirus.

Cytokines – proteins produced by immune cells – are responsible for severe overreactions by the immune system, known as cytokine storms, associated with COVID-19 and other serious illnesses. Cytokine storms are typically associated with an established group of cytokines. The researchers identified 57 COVID-19 patients treated at UVA who ultimately required a ventilator and then tested their blood samples within 48 hours of diagnosis or hospital admission. They compared the results with those from patients who did not end up needing a ventilator. The researchers found that the best predictor of COVID-19 outcomes was an “underappreciated” cytokine more associated with allergies. High levels of that cytokine, IL-13, were associated with worsened COVID-19 outcomes regardless of patients’ gender, age or other health problems.

The researchers also identified two more cytokines associated with severe outcomes, though the duo had less ability to predict the need for a ventilator. The researchers say the discovery could become part of a scoring system to let doctors flag up at-risk COVID-19 patients for closer monitoring and personalized interventions. In addition, the researchers found that levels of two other cytokines were significantly higher in patients with elevated blood sugar. This “proinflammatory response” could help explain why diabetes is associated with worse COVID-19 outcomes, according to the researchers.

“The immune response that we discovered to predict severe shortness of breath in COVID-19 is known in other pulmonary diseases to cause damage. So this could lead to a novel way to prevent respiratory failure in individuals infected with the new coronavirus, by inhibiting this immune cytokine,” said Bill Petri, MD, PhD, of UVA’s Division of Infectious Diseases and International Health. “We plan to test this in a model of COVID-19 prior to considering a clinical trial.”

Related Links:
University of Virginia School of Medicine


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.